Journal profile · ONCOLOGY
Oncology Letters
ISSN 1792-1074 · eISSN 1792-1082 · Spandidos Publications · GREECE · Founded 2010
Oncology Letters: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.13; fully open access; median 142 days to acceptance (101 articles, last 24 months); community-reported acceptance: about 72.72%; 585 articles in 2025; indexed in SCIE and Scopus; flagged on an early-warning list or for an indexing change: check before submitting.
Scope
Aims, scope and focus
Oncology Letters is published by Spandidos Publications and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer-related molecular mechanisms research, MicroRNA in disease regulation and Circular RNAs in diseases, together about 29.6% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief DEMETRIOS A. SPANDIDOSPublisher website
Editorial board by country: none in mainland China; most named Italy 6, Japan 5, Greece 4, Saudi Arabia 3, United Kingdom 2 (26 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology11.4%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology10.6%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology7.7%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology7.5%
- Cancer Cells and MetastasisMedicine4.4%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.2%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology3.9%
- Lung Cancer Treatments and MutationsMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
Early warning / risk: CAS Early Warning Journal List: listed in the 2020 edition (medium risk); not listed in the other 5 editions.LetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.13LetPub ·
- Impact factor (publisher)
- 2.1Publisher website ·
- CiteScore 2026-06
- 3.7LetPub ·
- CiteScore (publisher)
- 3.7Publisher website ·
- SJR 2026-06
- 0.65LetPub ·
- SNIP 2026-06
- 0.61LetPub ·
- h-index
- 38LetPub ·
- h-index
- 106OpenAlex ·
- i10-index
- 8,882OpenAlex ·
- 2-year mean citedness
- 2.17OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 99.32%LetPub ·
Volume
- Articles per year
- 545LetPub ·
Articles by year OpenAlex count · 15,854 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 442 | 442 | 243 |
| 2025 | 585 | 585 | 1,018 |
| 2024 | 651 | 651 | 2,380 |
| 2023 | 551 | 551 | 3,404 |
| 2022 | 474 | 474 | 4,878 |
| 2021 | 757 | 757 | 11,030 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
142 daysMedian, submission to acceptance · P25–P75 97 days – 197 days
- Acceptance to online
- median 36 days (102 articles)
- Submission to online
- median 189 days
- Sample
- 101 articles with submission and acceptance dates (1,242 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 72.72%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
Other charges and waivers (author guidelines)
- Page charges
- EUR 110
- Submission fee
- EUR 550
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- 150–300 words
- Keywords
- 5–10
- Reference style
- Numbered, in order of citation
- Cover letter
- Required
- Not considered
- title page; running title; font
Policy excerpts from the journal's websiteAI use, Conflicts of interest, Data availability, License & copyright, Open access, Self-archiving
- AI use Use of artificial intelligence tools
Authors should disclose the use of artificial intelligence (AI)-assisted tools such as chatGPT in the Declarations section (e.g. ‘Use of artificial intelligence tools - During the preparation of this work, AI tools were used to improve the readability and language of the manuscript or to generate images, and subsequently, the authors revised and edited the content produced by the AI tools as neces…
Source ↗Publisher website ·- Conflicts of interest Competing interests
Authors, reviewers and editors must disclose any competing interests that may exist with respect to the publication of a study. Competing interests are at play if the interpretation and presentation of the data, the conclusions or any other information provided by the authors can be influenced (or may be perceived as such) by their personal or financial relationship with other individuals or organ…
Source ↗Publisher website ·- Data availability Availability of data and materials
For all manuscripts submitted to Spandidos Publications, the authors must make provisions for all materials described in their manuscript, including all relevant raw data, to be freely available to any researchers who may wish to reuse or reanalyze them. If any conclusions made in the paper depend on a particular, dataset, then this dataset must be made available to the readers (unless it is alrea…
Source ↗Publisher website ·- License & copyright 3.3.9 Copyright
If a figure or table has been published previously (even if you were the author of the manuscript), copyright permission for re-use of the figure or table will often be required. You must acknowledge the original source and submit written permission from the copyright holder to reproduce the material where necessary. As an author of your manuscript, you are responsible for obtaining permissions to…
Source ↗Publisher website ·- Open access 7. Open access
"Open access" articles published online can be freely accessed at the journal's website by all users. The articles are made immediately available as Open access and appear online at PubMed, PubMed Central and Europe PMC. Articles may be licensed under a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International License, a Creative Commons Attribution-NonCommercial 4.0 Internationa…
Source ↗Publisher website ·- Self-archiving 10. Author self-archiving
Authors are encouraged to submit the final publisher’s version PDF of their manuscript to their institution’s repository 6 months following publication, as well as to their funding body’s archive. A link to the published version on the Spandidos Publications website must be included with full citation details and acknowledgement of the journal as the original source. Authors that have purchased Op…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Spandidos Publications
- Country or region
- GREECE
- Language
- English
- Founded
- 2010
- ISSN
- 1792-1074
- Electronic ISSN
- 1792-1082
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Oncology Letters
What CAS zone is Oncology Letters in?
In the 2025 upgraded edition of the CAS Journal Ranking, Oncology Letters is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Oncology Letters?
The latest impact factor listed by LetPub is 2.13; CiteScore 3.7, h-index 106.
How long does peer review take at Oncology Letters?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 142 days (interquartile range 97–197 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 72.72%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Oncology Letters?
According to the journal's author guidelines: Abstract: 150–300 words; Keywords: 5–10; Reference style: Numbered, in order of citation; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Oncology Letters based?
Of the 26 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (6), Japan (5) and Greece (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Oncology Letters?
According to LetPub and DOAJ records, Oncology Letters is indexed in SCIE and Scopus.
Is Oncology Letters open access, and what is the APC?
Oncology Letters is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .